An ‘AI Scientist’ Can Tackle Drug R&D. What Does that Mean for Pharma?
AI agents are moving from analytical tools to autonomous coworkers in pharma, with Owkin’s K Pro platform acting as an “AI scientist” that can answer complex research questions in hours rather than weeks. The system pulls together literature, gene‑expression data, and patient records from over 800 hospitals to generate validated plots and citations. Early adopters such as Novo Nordisk, Johnson & Johnson and other major firms are already testing customized agents, promising to speed discovery and reduce costs. Executives see the technology as a productivity multiplier rather than a job‑replacer, potentially expanding drug pipelines and top‑line growth.
New Data Build Case for Roche's Oral BTK Drug for MS
Roche reported that its oral BTK inhibitor fenebrutinib dramatically reduced relapse rates and MRI lesions in two phase 3 FENhance trials for relapsing multiple sclerosis, outperforming Sanofi's Aubagio. The drug cut annualised relapse rates by 51.1% and 58.5% and lowered inflammation...
Epstein-Barr Virus Methylation Aids Nasopharyngeal Cancer Screening
Researchers led by Wu, Z.C. and colleagues introduced an Epstein‑Barr virus (EBV) Cp methylation assay that triages individuals for nasopharyngeal carcinoma (NPC) risk. The method, published in Nature Communications, leverages viral DNA methylation patterns from nasopharyngeal swabs to achieve higher...
Tees, Esk and Wear Talking Therapies Improvement Challenge Highlights Steps to Improve Uptake of Digital
Tees, Esk and Wear Valleys NHS Foundation Trust completed a 100‑day improvement challenge aimed at boosting confidence among adults 65+ in using digital talking‑therapies. Over 240 seniors participated, with 96% reporting regular use of phones, tablets or laptops. Video‑based therapy...
Regeneron Reports P-III (NIMBLE) Trial Data on Cemdisiran for Generalized Myasthenia Gravis (gMG)
Regeneron presented Phase III (NIMBLE) data showing that subcutaneous cemdisiran 600 mg every 12 weeks significantly improved symptoms in adults with generalized myasthenia gravis (gMG) and anti‑AChR antibodies. Over 24 weeks, the cemdisiran arm reduced MG‑ADL scores by 4.5 points versus 2.2...
Elevance Health Profits Eclipse $1.7 Billion Despite Elevated Costs
Elevance Health reported first‑quarter net income of $1.76 billion, a 17% decline from a year earlier, while total revenue rose 2.6% to $50.18 billion. The company’s benefit‑expense ratio climbed to 86.8%, reflecting higher medical costs in its Medicaid business despite modest gains...
Merck Steps up as 'Meaningful Competitor' To Gilead with HIV Pill Approval
Merck received FDA approval for Idvynso, a once‑daily, single‑pill regimen for virologically suppressed HIV‑1 adults, slated for U.S. launch on May 11, 2026. The drug demonstrated non‑inferior viral suppression versus continued Biktarvy use in two pivotal trials. Analysts see Idvynso...
Merck to Partner with Google Cloud on AI Initiatives
Merck & Co announced a partnership with Google Cloud to accelerate its artificial‑intelligence capabilities, allocating up to $1 billion over several years. The deal will fund AI infrastructure, licensing of Google’s Gemini Enterprise platform, and dedicated cloud engineers working alongside Merck...
A ‘Barbaric’ Problem in American Hospitals Is Only Getting Bigger
A personal account of a dying husband’s prolonged stays in emergency‑department (ED) boarding highlights a growing crisis in U.S. hospitals. Patients are often kept on stretchers in hallways for 24‑plus hours because inpatient beds are scarce, a problem that has...
FDA Approves MSD’s Once-Daily HIV Combo Idvynso
Merck’s Idvynso (doravirine/islatravir) received FDA approval, marking the first tenofovir‑free, non‑INSTI two‑drug regimen for HIV. The decision follows Phase III trials that demonstrated non‑inferior viral suppression compared with Gilead’s three‑drug standard Biktarvy. Idvynso targets virologically suppressed patients without prior treatment failure...
7 Reasons Traveling For Drug Rehab Improves Treatment Outcomes Nationwide
Traveling for drug rehabilitation acts as an environmental reset that removes patients from familiar triggers, improves detox stabilization, and boosts clinical engagement. Relocating patients enables access to specialized, evidence‑based programs and a highly structured daily routine. The broader perspective gained...
What to Know About the U.K.’s Generational Smoking Ban
The UK Parliament has approved the Tobacco and Vapes Bill, which will ban the sale of cigarettes, herbal smoking products and cigarette paper to anyone born in 2009 or later, creating a “smoke‑free” generation. The legislation also expands vape‑free zones...
Ipsen’s Ojemda (Tovorafenib) Receives Conditional Approval for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG) in the EU
Ipsen’s oral kinase inhibitor Ojemda (tovorafenib) received conditional approval from the European Commission for treating pediatric low‑grade glioma (pLGG) with BRAF fusions, rearrangements or V600 mutations. The indication applies to patients six months or older who have progressed after at...
The UK Passes A Lifetime Smoking Ban. Could America Be Next?
The UK Parliament approved the Tobacco and Vapes Bill, which will permanently bar anyone born on or after Jan. 1, 2009 from purchasing tobacco, with the law taking effect on Jan. 1, 2027. The measure raises the legal smoking age by one year each...
Gene Variant, RSV Bronchiolitis Linked to Male Asthma
A new longitudinal study of 3,200 infants found that a common variant in the 17q21 locus dramatically amplifies the risk of developing asthma after early‑life respiratory syncytial virus (RSV) bronchiolitis, but only in male children. Boys carrying the risk allele...
What Leading Planned Parenthood Is Like Now
Since taking the helm in 2020, Alexis McGill Johnson has steered Planned Parenthood through a post‑Dobbs landscape marked by federal defunding, a wave of clinic closures and a shifting political spotlight. The organization, once operating over 600 health centers, has lost 53...
Can Biotech Finally Fix Infertility?
Infertility affects one in six adults worldwide, yet current care relies heavily on IVF, which still yields modest pregnancy rates—33% per transfer for standard cycles and 51% for egg donation. Biotech firms are targeting the biological gaps that IVF bypasses,...
Expanded HSA Eligibility Creates Need for Employee Education: 4 Critical Tips
Recent legislation expands Health Savings Account eligibility to bronze and silver Affordable Care Act plans, opening HSA participation to a broader employee base. Employers can now tap this tax‑advantaged tool to help workers manage current medical costs and build retirement...
Robotic Phlebotomy Study Signals Automation Shift for Clinical Labs
Vitestro’s autonomous robotic phlebotomy system Aletta completed a multicenter ADOPT trial involving 1,633 patients, achieving a 94.5% first‑stick success rate and markedly low hemolysis (0.3%) and adverse events (0.6%). Patient surveys showed 90% experienced equal or less pain, with 82%...
Rapid Blood Infection Test Fails to Improve Survival
A large, open‑label randomized trial of 899 patients with gram‑negative bacteremia compared rapid antimicrobial susceptibility testing directly from positive blood cultures to standard sub‑culture testing. The rapid approach delivered susceptibility results in about 7.5 hours versus 44 hours for the conventional method,...
New Nanomedicine Approach Boosts Chemotherapy And Immune Activity In Pancreatic Cancer
A preclinical mouse study published in Advanced Science demonstrates that photoactivatable multi‑inhibitor liposomes (PMILs) can deliver irinotecan directly to pancreatic ductal adenocarcinoma (PDAC) tumors when activated by light. The regimen combines minocycline‑mediated DNA‑repair inhibition, photodynamic priming, and localized chemotherapy, boosting...
Will Your Retirement Income Trigger the IRMAA This Year? (Plus, 6 Ways to Avoid It in the Future)
The article explains how the income‑related monthly adjustment amount (IRMAA) raises Medicare Part B and D premiums for retirees whose 2024 modified adjusted gross income (MAGI) exceeds $108,000 for single filers or $218,000 for married couples. Even a single dollar over...
BioAegis and Prenosis Partner for Inflammatory Disease Therapies
BioAegis Therapeutics has teamed up with AI‑focused startup Prenosis to accelerate precision‑medicine approaches for inflammatory diseases. The partnership will analyze biospecimens from BioAegis’s Phase II BTI‑203 trial of recombinant human plasma gelsolin in 600 ARDS patients across Europe, Canada and the...
Why Advisers Must Move From 'Retailers' To 'Guardians'
U.S. commercial healthcare consumes about $1.3 trillion annually, with roughly $325 billion—equivalent to a $4,000 per‑employee leak—attributed to administrative waste and opaque PBM pricing. Traditional benefits brokers earn commissions tied to premium volume, creating a direct conflict between adviser income and client...
Medicare Obesity Drug Pilot Extended After Insurer Pushback
The Trump administration has pushed back the start of the Medicare GLP‑1 Bridge pilot by a year after insurers fell short of the 80% enrollment target. The federal government will continue to cover drugs such as Novo Nordisk’s Wegovy, Eli Lilly’s...
4 Medications That May Increase Dementia Risk
Recent health reports highlight that certain over‑the‑counter and prescription drugs, especially anticholinergic antihistamines, may raise dementia risk by about 50 percent. While medications like statins and some blood‑pressure treatments appear protective, the evidence linking anticholinergics to cognitive decline stems mainly...
Senators Grill RFK Jr. On Vaccines, Drug Prices and More at Hearing
Health Secretary Robert F. Kennedy Jr. faced intense questioning from Senate Finance and HELP committees, with Democrats probing his vaccine policies, promotional video costs, and the TrumpRx drug‑discount platform. Republicans highlighted his rural health initiatives and progress on food‑dye reductions,...
Amazon Just Put the Biggest Trade of the Decade on the Wrong Side—And Big Pharma Is Paying for It
Amazon has launched a direct‑to‑patient pricing model for GLP‑1 drugs, offering cash‑pay rates of $25 per month for insured patients, $149 for oral pills and $299 for injectables such as Wegovy and Zepbound. The pricing, combined with same‑day delivery to...
They’re in Remission, but Their Medical Bills Aren’t: Cancer Survivors Navigate Soaring Costs
Cancer survivors in the United States are confronting soaring out‑of‑pocket expenses even after remission. The article follows Marielle Santos McLeod, who continues to pay thousands in chemotherapy and follow‑up bills, and cites a 2024 survey showing 47 % of survivors carry medical...
Montana Moves Ahead With Doula Pay but Warns Medicaid Cuts Still May Come
Montana officials reversed a pause and are moving ahead with a plan to reimburse doulas through Medicaid, estimating a first‑year cost of about $118,000. The initiative, approved by lawmakers last year, still requires federal approval before payments can start. State...
On‐Chip Evaluation of Red Blood Cell Deformability Through Transit Velocity Index in Hematological Diseases
Researchers have introduced a microfluidic platform that measures red blood cell (RBC) deformability using a transit velocity index (V^ε=0.5) derived from capillary‑like constrictions. The index reliably tracks stiffness changes when RBCs are chemically stiffened with diamide, confirming its sensitivity. Applying...
Genentech Reports the P-III (METEOROID) Trial Data on Enspryng (Satralizumab) to Treat MOGAD
Genentech presented Phase III METEOROID trial results for Enspryng (satralizumab) in patients aged 12 and older with myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD). The study met its primary endpoint, showing 87% of participants remained relapse‑free at 48 weeks versus 67%...
Firefighters to Get Regular Health Checks Under New ‘Concordat’
The UK government has signed a Firefighters Concordat on Health and Wellbeing, committing to regular health checks for all firefighters and new research funding. Health and Social Care Secretary Wes Streeting and Building Safety Minister Samantha Dixon announced the initiative...
Artera’s Prostate Biopsy and Breast Cancer Assays Receive CE Mark
Artera announced that its ArteraAI prostate biopsy and breast cancer assays have received CE marking under the EU In Vitro Diagnostic Regulation, expanding the company’s reach to the European market. The prostate assay is the first AI‑enabled prognostic and predictive test...
PARP Inhibitors: A Proven Class Facing Limits
PARP inhibitors have reshaped treatment for BRCA‑mutated cancers by exploiting synthetic lethality, but their expansion beyond this niche faces hurdles. While ovarian, breast, pancreatic, and prostate indications now include PARP‑based maintenance or combination regimens, inconsistent benefits in HRD‑positive and broader...
PSN Manufacturing Earns ISO 9001 and 13485 Certifications
PSN Manufacturing announced it has earned ISO 9001:2015 and ISO 13485:2016 certifications, confirming a robust quality management system for both general manufacturing and regulated medical‑device components. The company’s 100% climate‑controlled plant features a Class 8 cleanroom, a flexible molding floor for 50‑500 ton machines,...
How Indian Families Can Optimise Floater Health Plans
Indian families are urged to treat floater health insurance as a strategic, not just a convenience, purchase. The article outlines how aligning policy structure with age mix, medical needs, and potential claim overlap can improve coverage efficiency. It stresses the...
Roche Reports Phase III METEOROID Study Results for MOGAD
Roche announced that its subcutaneous antibody satralizumab, marketed as Enspryng, achieved a 68% reduction in relapse risk in the Phase III METEOROID trial for myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD). At 48 weeks, 87% of patients on Enspryng remained relapse‑free versus...
Register for HTN Now Webinars, Covering AVT in Trusts, Digital Patient Pathways, AI in Primary Care, 10 Year Plan From...
HTN is launching a series of free, online webinars for NHS professionals that run from late April through May. Each session deep‑dives into a specific digital‑health topic, from ambient‑scribe AI and paperless NHS initiatives to AI in primary care and...
Sanofi Reports the US FDA Approval of Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Children (≥1years)
Sanofi’s monoclonal antibody Tzield (teplizumab‑mzwv) received U.S. FDA approval under priority review to delay the onset of stage 3 type 1 diabetes (T1D) in children as young as one year who are diagnosed with stage 2 disease. The decision was driven by one‑year...
National Commission Into the Regulation of AI in Healthcare Offers Early Insights From Call for Evidence
The UK National Commission into the Regulation of AI in Healthcare released early findings from a call for evidence that attracted more than 770 responses, underscoring strong public demand for regulatory reform. Deputy chair Henrietta Hughes emphasized trust, post‑market surveillance,...
New "Plug-and-Play" AI Outperforms Pathologists in Lymph Node Metastasis Detection
HKUST researchers unveiled PRET, a plug‑and‑play AI pathology system that learns new cancer types from just one to eight annotated slides. The model achieved AUC scores above 97% on 15 of 20 benchmark tasks, including a perfect 100% for colorectal...
Lentinan‐Enhanced Mn3O4 Nanoparticles for Neuroinflammation Relief and Parkinson's Disease Treatment
Researchers have engineered a lentinan‑coated manganese oxide (Mn3O4@LNT) nanoparticle that can circulate long‑term and cross the blood‑brain barrier (BBB). Proteomic analysis revealed that the LNT coating reshapes the particle’s protein corona, enhancing BBB traversal and brain accumulation. In cellular and...
The World’s First RealTime AI Assistant for Pancreatic EUS, Available for Clinical Use in the UK.
Fannin UK has launched mAI Companion®, a real‑time AI assistant for pancreatic endoscopic ultrasound (EUS) that received MDR CE Mark approval, making it the first AI‑driven EUS tool cleared for clinical use in the UK. Developed with IHU‑Strasbourg and trained...
Roche’s Fenebrutinib Cuts Relapses in MS Amid Safety Concerns
Roche’s investigational BTK inhibitor fenebrutinib achieved 51.1% and 58.5% reductions in annualised relapse rates versus teriflunomide in the Phase III FENhance 1 and 2 trials for relapsing multiple sclerosis, while also cutting MRI lesion activity. The drug showed encouraging trends in disability‑progression measures...
Merck Reports the US FDA Approval of Idvynso for Virologically Suppressed HIV-1 Infection
Merck’s Idvynso, a once‑daily tablet combining 100 mg doravirine with 0.25 mg islatravir, received FDA approval as a switch regimen for virologically suppressed HIV‑1 adults. The approval rests on two Phase III trials—Trial 052 (n=513) and Trial 051 (n=551)—which demonstrated comparable viral suppression to existing...
Taste Alterations in Breast Cancer Patients Undergoing Chemotherapy: An Observational Study
A prospective study at Italy’s Candiolo Cancer Institute enrolled 94 breast‑cancer patients, with 70 completing chemotherapy and taste assessments. Subjective questionnaires showed a marked decline in all taste modalities after treatment, while objective taste‑strip testing identified hypogeusia in roughly one‑third...
The Effect of Breast Massage Combined with Co-Parenting Interventions on Breastfeeding in Mother-Infant Separated Mothers: A Quasi-Experimental Study
A quasi‑experimental trial involving 120 mother‑infant dyads separated after birth tested a co‑parenting protocol where fathers performed structured breast massage. The intervention group achieved exclusive breastfeeding rates of 64.9% at one month and 64.3% at three months, far surpassing the...
Hypoallergenicity of a Hydrolyzed Rice Protein-Based Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Children with Cow’s Milk Allergy: Protocol for a...
The RIGHT‑HY study is a multicenter, double‑blind, crossover trial evaluating a hydrolyzed rice protein formula enriched with the human milk oligosaccharides 2‑fucosyllactose and lacto‑N‑neotetraose (HRF‑HMO) in children aged 60 days to 3 years with IgE‑mediated cow’s milk allergy (CMA). Up to 67...
New Algorithms Help Surgeons Make High-Stakes Transplant Decisions in Minutes
Researchers at the ISHLT meeting unveiled AI tools designed to speed heart‑transplant decisions, aiming to cut the 15‑30 minute evaluation window. The flagship model, TOPHAT, analyzes 20 donor variables to predict a center’s likelihood of accepting a heart, while a...